A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91206
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men and non-childbearing potential women
- Body mass index between 18.0-32.0 kilograms per square meter (kg/m^2)
- Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies
Exclusion Criteria:
- Taking over-the-counter or prescription medication with the exception of vitamins or minerals
- Smoke more than 10 cigarettes per day
- Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Administered orally as capsules, daily for 14 days
|
|
Experimental: LY2886721
|
5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Clinically Significant Effects
Time Frame: Predose up to Day 70
|
Clinically significant effects were defined as serious and nonserious adverse events.
A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module.
The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.
|
Predose up to Day 70
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721
Time Frame: Predose (Day 14) up to Day 19
|
Predose (Day 14) up to Day 19
|
|
|
Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721
Time Frame: Predose (Day 14) to 24 Hours post-dose (Day 15)
|
Area under the concentration versus time curve during 1 dosing interval (1 dosing interval=24 hours) at steady state (AUCτ,ss) is being reported for this outcome measure.
|
Predose (Day 14) to 24 Hours post-dose (Day 15)
|
|
Plasma Amyloid Beta (Aβ) 1-40 Concentration
Time Frame: Predose (Day 14) up to Day 19
|
The minimum concentration (Cnadir) is being reported for this outcome measure.
|
Predose (Day 14) up to Day 19
|
|
Cerebrospinal Fluid (CSF) Concentration of LY2886721
Time Frame: 24 Hours post-dose (Day 15)
|
24 Hours post-dose (Day 15)
|
|
|
Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration
Time Frame: Predose (Day 14), 24 Hours post-dose (Day 15)
|
The Least Squares means were adjusted for baseline concentration.
|
Predose (Day 14), 24 Hours post-dose (Day 15)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 13734
- I4O-MC-BACB (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.